Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …

Rituximab has become a ubiquitous component of treatment regimens for follicular non-
Hodgkin lymphoma. Despite widespread clinical use, the mechanisms by which tumor cells …

Objectives Autologous chimeric antigen receptor (CAR) αβ T‐cell therapies have
demonstrated remarkable antitumor efficacy in patients with haematological malignancies; …

Background Post-transplantation lymphoproliferative disorder (PTLD) develops in 1–10% of
transplant recipients and can be Epstein–Barr virus (EBV) associated. To improve long-term …

Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the
treatment of a variety of malignant and autoimmune disorders. Despite this success, a …

GAUGUIN evaluated the safety and efficacy of obinutuzumab (GA101) monotherapy in
patients with relapsed/refractory chronic lymphocytic leukemia (CLL). In phase 1 (dose …

In the last two decades, monoclonal antibodies have revolutionized the therapy of cancer
patients. Although antibody therapy has continuously been improved, still a significant …

Monoclonal antibodies (mAbs) are currently the largest and most dominant class of
therapeutic proteins. Inter-individual variability has been observed for several mAbs; …

New treatments are required for rituximab-refractory follicular lymphoma (FL). In the present
study, patients with rituximab-refractory FL received 8 weekly infusions of ofatumumab …

Monoclonal antibodies (mAbs) are usually delivered systemically, but only a small
proportion of the drug reaches the lung after intravenous injection. The inhalation route is an …